Role of anti-osteopontin antibodies in multiple sclerosis and experimental autoimmune encephalomyelitis

Frontiers in Immunology

Volumn 8, Issue MAR, 2017, Pages

  Clemente, Nausicaa ^a   Comi, Cristoforo ^a   Raineri, Davide ^a   Cappellano, Giuseppe ^b   Vecchio, Domizia ^a   Orilieri, Elisabetta ^a   Gigliotti, Casimiro L ^a   Boggio, Elena ^a   Dianzani, Chiara ^c   Sorosina, Melissa ^d   Martinelli Boneschi, Filippo ^d   Caldano, Marzia ^e   Bertolotto, Antonio ^e   Ambrogio, Luca ^f   Sblattero, Daniele ^g   Cena, Tiziana ^a   Leone, Maurizio ^h   Dianzani, Umberto ^a   Chiocchetti, Annalisa ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF TURIN   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^f S CROCE E CARLE HOSPITAL   (Italy)

^g UNIVERSITY OF TRIESTE   (Italy)

^h CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Autoantibodies; Experimental autoimmune encephalomyelitis; Multiple sclerosis; osteopontin; Vaccination

Indexed keywords

AUTOANTIBODY; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; OSTEOPONTIN;

ADULT; ANIMAL CELL; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CELL DEATH; CELL SURVIVAL; CLINICAL OUTCOME; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; CYTOKINE RELEASE; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; RECURRENT DISEASE; REMISSION; SPLEEN LYMPHOCYTE; THYMIDINE INCORPORATION ASSAY; VACCINATION; WESTERN BLOTTING;

EID: 85017092388     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00321     Document Type: Article

References (44)

1. Zettl UK, Stüve O, Patejdl R. Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun Rev (2012) 11(3):167-73. doi: 10.1016/j.autrev.2011.05.008
2. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin (1995) 13(1):119-46
3. Harris VK, Sadiq SA. Biomarkers of therapeutic response in multiple sclerosis: current status. Mol Diagn Ther (2014) 18(6):605-17. doi:10.1007/s40291-014-0117-0
4. Carecchio M, Comi C. The role of osteopontin in neurodegenerative diseases. J Alzheimers Dis (2011) 25(2):179-85. doi:10.3233/JAD-2011-102151
5. Gravallese EM. Osteopontin: a bridge between bone and the immune system. J Clin Invest (2003) 112(2):147-9. doi:10.3233/JAD-2011-102151
6. Chiocchetti A, Comi C, Indelicato M, Castelli L, Mesturini R, Bensi T, et al. Osteopontin gene haplotypes correlate with multiple sclerosis development and progression. J Neuroimmunol (2005) 163(1-2):172-8. doi:10.1016/j.jneuroim.2005.02.020
7. Sennels H, Sørensen S, Ostergaard M, Knudsen L, Hansen M, Skjødt H, et al. Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. Scand J Rheumatol (2008) 37(4):241-7. doi:10.1080/03009740801910320
8. D'Alfonso S, Barizzone N, Giordano M, Chiocchetti A, Magnani C, Castelli L, et al. Two single-nucleotide polymorphisms in the 5' and 3' ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum (2005) 52(2):539-47. doi:10.1002/art.20808
9. Mishima R, Takeshima F, Sawai T, Ohba K, Ohnita K, Isomoto H, et al. High plasma osteopontin levels in patients with inflammatory bowel disease. J Clin Gastroenterol (2007) 41(2):167-72. doi:10.1097/MCG.0b013e31802d6268
10. Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science (2001) 294(5547):1731-5. doi:10.1126/science.1062960
11. Braitch M, Constantinescu CS. The role of osteopontin in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS). Inflamm Allergy Drug Targets (2010) 9(4):249-56. doi:10.2174/187152810793358778
12. Comabella M, Pericot I, Goertsches R, Nos C, Castillo M, Blas Navarro J, et al. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol (2005) 158(1-2):231-9. doi:10.1016/j.jneuroim.2004.09.004
13. Comi C, Cappellano G, Chiocchetti A, Orilieri E, Buttini S, Ghezzi L, et al. The impact of osteopontin gene variations on multiple sclerosis development and progression. Clin Dev Immunol (2012) 2012:212893. doi:10.1155/2012/212893
14. Yokosaki Y, Matsuura N, Sasaki T, Murakami I, Schneider H, Higashiyama S, et al. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem (1999) 274(51):36328-34. doi:10.1074/jbc.274.51.36328
15. Murugaiyan G, Mittal A, Weiner HL. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol (2008) 181(11):7480-8. doi:10.4049/jimmunol.181.11.7480
16. Wolak T, Sion-Vardi N, Novack V, Greenberg G, Szendro G, Tarnovscki T, et al. N-terminal rather than full-length osteopontin orits C-terminal fragment is associated with carotid-plaque inflammation inhypertensive patients. Am J Hypertens (2013) 26(3):326-33. doi:10.1093/ajh/hps043
17. Boggio E, Dianzani C, Gigliotti CL, Soluri MF, Clemente N, Cappellano G, et al. Thrombin cleavage of osteopontin modulates its activities in human cells in vitro and mouse experimental autoimmune encephalomyelitis in vivo. J Immunol Res (2016) 2016:9345495. doi:10.1155/2016/9345495
18. Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol (2007) 8(1):74-83. doi:10.1038/ni1415
19. Steinman L, Youssef S, Van Venrooij N, Chabas D, Baranzini SE, Rittling S, et al. Response to comment on "the influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease". Science (2003) 299(5614):1845. doi:10.1126/science.1080223
20. Sakata M, Tsuruha JI, Masuko-Hongo K, Nakamura H, Matsui T, Sudo A, et al. Autoantibodies to osteopontin in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol (2001) 28(7):1492-5
21. Fan K, Dai J, Wang H, Wei H, Cao Z, Hou S, et al. Treatment of collagen-induced arthritis with ananti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis Rheum (2008) 58(7):2041-52. doi:10.1002/art.23490
22. Cappellano G, Orilieri E, Woldetsadik AD, Boggio E, Soluri MF, Comi C, et al. Anti-cytokine autoantibodies in autoimmune diseases. Am J Clin Exp Immunol (2012) 1(2):136-46
23. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 50(1):121-7. doi:10.1002/ana.1032
24. Leone MA, Bonissoni S, Collimedaglia L, Tesser F, Calzoni S, Stecco A, et al. Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study. Mult Scler (2008) 14(4):485-93. doi:10.1177/1352458507084650
25. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, et al. Multiple sclerosis severity score: using disability and disease duration torate disease severity. Neurology (2005) 64(7):1144-51. doi:10.1212/01.WNL.0000156155.19270.F8
26. Uyttenhove C, Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol (2006) 36(11):2868-74. doi:10.1002/eji.200636662
27. Cappellano G, Woldetsadik AD, Orilieri E, Shivakumar Y, Rizzi M, Carniato F, et al. Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis. Vaccine (2014) 32(43):5681-9. doi:10.1016/j.vaccine.2014.08.016
28. Sblattero D, Bradbury A. Exploiting recombination in single bacteria to make large phage antibody libraries. Nat Biotechnol (2000) 18(1):75-80. doi:10.1038/71958
29. Di Niro R, Ziller F, Florian F, Crovella S, Stebel M, Bestagno M, et al. Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models. BMC Biotechnol (2007) 7:46. doi:10.1186/1472-6750-7-46
30. Milo R. Therapeutic strategies targeting B-cells in multiple sclerosis. Autoimmun Rev (2016) 15(7):714-8. doi:10.1016/j.autrev.2016.03.006
31. Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, et al. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol (2014) 13(4):353-63. doi:10.1016/S1474-4422(14)70028-6
32. Sergott RC, Bennett JL, Rieckmann P, Montalban X, Mikol D, Freudensprung U, et al. ATON: results from a phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis. J Neurol Sci (2015) 351(1-2):174-8. doi:10.1016/j.jns.2015.02.019
33. Nestorov I, Munafo A, Papasouliotis O, Visich J. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol (2008) 48(4):406-17. doi:10.1177/0091270008315312
34. Iaffaldano P, Ruggieri M, Viterbo RG, Mastrapasqua M, Trojano M. The improvement of cognitive functions is associated with a decrease of plasma osteopontin levels in natalizumab treated relapsing multiple sclerosis. Brain Behav Immun (2014) 35:96-101. doi:10.1016/j.bbi.2013.08.009
35. Shimizu Y, Ota K, Ikeguchi R, Kubo S, Kabasawa C, Uchiyama S. Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica. J Neuroimmunol (2013) 263(1-2):148-51. doi:10.1016/j.jneuroim.2013.07.005
36. Kivisäkk P, Healy BC, Francois K, Gandhi R, Gholipour T, Egorova S, et al. Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult Scler (2014) 20(4):438-44. doi:10.1177/1352458513503052
37. Runia TF, van Meurs M, Nasserinejad K, Hintzen RQ. No evidence for an association of osteopontin plasma levels with disease activity in multiple sclerosis. Mult Scler (2014) 20(12):1670-1. doi:10.1177/1352458514528765
38. Guan H, Nagarkatti PS, Nagarkatti M. CD44 reciprocally regulates the differentiation of encephalitogenic Th1/Th17 and Th2/regulatory T cells through epigenetic modulation involving DNA methylation of cytokine gene promoters, thereby controlling the development of experimental autoimmune encephalomyelitis. J Immunol (2011) 186(12):6955-64. doi:10.4049/jimmunol.1004043
39. Winkler CW, Foster SC, Matsumoto SG, Preston MA, Xing R, Bebo BF, et al. Hyaluronan anchored to activated CD44 on central nervous system vascular endothelial cells promotes lymphocyte extravasation in experimental autoimmune encephalomyelitis. J Biol Chem (2012) 287(40):33237-51. doi:10.1074/jbc.M112.356287
40. Flynn KM, Michaud M, Madri JA. CD44 deficiency contributes to enhanced experimental autoimmune encephalomyelitis: a role in immune cells and vascular cells of the blood-brain barrier. Am J Pathol (2013) 182(4):1322-36. doi:10.1016/j.ajpath.2013.01.003
41. Deboux C, Ladraa S, Cazaubon S, Ghribi-Mallah S, Weiss N, Chaverot N, et al. Overexpression of CD44 in neural precursor cells improves trans-endothelial migration and facilitates their invasion of perivascular tissues in vivo. PLoS One (2013) 8(2):e57430. doi:10.1371/journal.pone.0057430
42. Ghazi-Visser L, Laman JD, Nagel S, van Meurs M, van Riel D, Tzankov A, et al. CD44 variant isoforms control experimental autoimmune encephalomyelitis by affecting the lifespan of the pathogenic T cells. FASEB J (2013) 27(9):3683-701. doi:10.1096/fj.13-228809
43. Comi C, Fleetwood T, Dianzani U. The role of T cell apoptosis in nervous system autoimmunity. Autoimmun Rev (2012) 12(2):150-6. doi:10.1016/j.autrev.2011.08.011
44. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev (2008) 19(5-6):333-45. doi:10.1016/j.cytogfr.2008.08.001